Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.
Authors
Greystoke, AlastairO'Connor, James P B
Linton, Kim M
Taylor, M Ben
Cummings, Jeffrey
Ward, Timothy H
Maders, Fran
Hughes, Anthony
Ranson, Malcolm R
Illidge, Timothy M
Radford, John A
Dive, Caroline
Affiliation
Clinical and Experimental Pharmacology Group, The Paterson Institute for Cancer Research, The University of Manchester, Wilmslow Road, Withington, Manchester M20 4BX, UK.Issue Date
2011-02-15
Metadata
Show full item recordAbstract
Treatment efficacy and toxicity are difficult to predict in lymphoma patients. In this study, the utility of circulating biomarkers in predicting and/or monitoring treatment efficacy/toxicity were investigated.Citation
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. 2011, 104 (4):719-25 Br. J. CancerJournal
British Journal of CancerDOI
10.1038/sj.bjc.6606082PubMed ID
21245866PubMed Central ID
PMC3049589Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/sj.bjc.6606082
Scopus Count
Related articles
- Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
- Authors: Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y
- Issue date: 2014 Aug
- A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity.
- Authors: Gibb A, Greystoke A, Ranson M, Linton K, Neeson S, Hampson G, Illidge T, Smith E, Dive C, Pettitt A, Lister A, Johnson P, Radford J
- Issue date: 2013 Nov 12
- Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
- Authors: Borchmann P
- Issue date: 2014 Feb
- ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
- Authors: Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation., Gruppo Italiano di Terapie Innovative nei Linfomi., Intergruppo Italiano Linfomi.
- Issue date: 2011 Jul 21
- Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
- Authors: Go SI, Park MJ, Song HN, Kim HG, Kang MH, Lee HR, Kim Y, Kim RB, Lee SI, Lee GW
- Issue date: 2016 Dec